ARQT Arcutis Corp Earnings per share growth this year

Arcutis Biotherapeutics (ARQT) leverages significant pricing power by adapting potent biologics into safe topical treatments. A comparison of annual EPS growth on the GURU.Markets chart shows that 311.30 is the current metric value. Scaling Zoryve sales creates operational leverage, reducing unit costs. The increasing number of prescriptions and the expansion of US insurance coverage serve as the primary growth catalysts.
Comprehensive metric breakdowns and analytics for arcutis.com (ARQT)

Conservative capital demands profit transparency to assess long-term solvency and business sustainability. This indicator measures the annual change in earnings per share, allowing for the identification of the real profitability trend regardless of quarterly fluctuations. For Arcutis Biotherapeutics (ARQT), this annual percentage change in earnings per share is critical, as it reflects the effectiveness of drug commercialization against a backdrop of high marketing expenses.